Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors

NCT00790816 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00790816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00790816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2008
Completion date
August 19, 2016
Enrollment
500 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast